• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.

作者信息

Zhao Jessie, Khong Tiffany, Gorniak Malgorzata, Khaled Abir, McDonald Zac, Reynolds John, Mithraprabhu Sridurga, Bingham Nicholas, Lim Suehli, Wong Daniel, Johnston Anna, Motorna Olga, Murphy Nicholas, Quach Hang, Yang Liqiang, Spencer Andrew

机构信息

Department of Malignant Haematology and Stem Cell Transplantation, The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne.

Alfred Pathology, The Alfred Hospital, Melbourne.

出版信息

Haematologica. 2025 Mar 1;110(3):764-767. doi: 10.3324/haematol.2024.285933.

DOI:10.3324/haematol.2024.285933
PMID:39506908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11873694/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3639/11873694/94befdfbe315/110764.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3639/11873694/bd082bb82459/110764.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3639/11873694/94befdfbe315/110764.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3639/11873694/bd082bb82459/110764.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3639/11873694/94befdfbe315/110764.fig2.jpg

相似文献

1
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.克隆型质谱分析方法EasyM与EuroFlow在多发性骨髓瘤微小残留病评估中的比较。
Haematologica. 2025 Mar 1;110(3):764-767. doi: 10.3324/haematol.2024.285933.
2
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).采用质谱法（EasyM）靶向跟踪血清 M 蛋白监测多发性骨髓瘤患者的微小残留病灶。
Clin Cancer Res. 2024 Mar 15;30(6):1131-1142. doi: 10.1158/1078-0432.CCR-23-2767.
3
A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).基于个性化质谱分析的多发性骨髓瘤患者 M 蛋白监测方法（EasyM）。
Clin Cancer Res. 2021 Sep 15;27(18):5028-5037. doi: 10.1158/1078-0432.CCR-21-0649. Epub 2021 Jul 1.
4
Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.采用SRL 8色单管和EuroFlow 8色2管多参数流式细胞术检测多发性骨髓瘤微小残留病的比较
Int J Hematol. 2019 Apr;109(4):377-381. doi: 10.1007/s12185-019-02615-z. Epub 2019 Feb 18.
5
Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.多发性骨髓瘤微小残留病灶检测：BML 单管十色多参数流式细胞术与 EuroFlow 多参数流式细胞术的比较。
Ann Hematol. 2021 Dec;100(12):2989-2995. doi: 10.1007/s00277-021-04634-5. Epub 2021 Aug 25.
6
Retraction Note to: EuroFlow-Based Next-Generation Flow Cytometry for Detection of Circulating Tumor Cells and Minimal Residual Disease in Multiple Myeloma.撤稿说明：基于欧洲流式细胞术的新一代流式细胞术用于检测多发性骨髓瘤中的循环肿瘤细胞和微小残留病
Methods Mol Biol. 2018;1792:E1. doi: 10.1007/978-1-4939-7865-6_16.
7
Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.DuraClone 与 EuroFlow 方法检测多发性骨髓瘤微小残留病的比较。
Sci Rep. 2021 May 27;11(1):11218. doi: 10.1038/s41598-021-89761-9.
8
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma.免疫球蛋白基因重排的克隆型特征可为多发性骨髓瘤微小残留病监测提供个性化的生物标志物。
Clin Chem. 2021 Jun 1;67(6):867-875. doi: 10.1093/clinchem/hvab017.
9
EuroFlow-Based Next-Generation Flow Cytometry for Detection of Circulating Tumor Cells and Minimal Residual Disease in Multiple Myeloma.基于欧洲流式细胞术标准（EuroFlow）的新一代流式细胞术用于检测多发性骨髓瘤中的循环肿瘤细胞和微小残留病
Methods Mol Biol. 2018;1792:15-34. doi: 10.1007/978-1-4939-7865-6_2.
10
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.多发性骨髓瘤中的微小残留病检测：MSKCC 10色单管法与EuroFlow 8色双管法的比较
Blood Adv. 2017 May 3;1(12):728-732. doi: 10.1182/bloodadvances.2016003715. eCollection 2017 May 9.

本文引用的文献

1
Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21.对于新诊断的适合移植的多发性骨髓瘤患者，在一线基于硼替佐米的诱导治疗失败后，采用达雷妥尤单抗-来那度胺-地塞米松进行反应适应性挽救治疗-ALLG MM21。
Br J Haematol. 2024 Sep;205(3):900-914. doi: 10.1111/bjh.19578. Epub 2024 Jun 8.
2
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).采用质谱法（EasyM）靶向跟踪血清 M 蛋白监测多发性骨髓瘤患者的微小残留病灶。
Clin Cancer Res. 2024 Mar 15;30(6):1131-1142. doi: 10.1158/1078-0432.CCR-23-2767.
3
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
适合移植的骨髓瘤患者中下一代测序微小残留病灶（MRD）和 PET 扫描的综合分析。
Blood Cancer J. 2023 Mar 6;13(1):32. doi: 10.1038/s41408-023-00794-x.
4
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.采用靶向质谱法对骨髓瘤微小残留病进行动态监测。
Blood Cancer J. 2023 Feb 24;13(1):30. doi: 10.1038/s41408-023-00803-z.
5
A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).基于个性化质谱分析的多发性骨髓瘤患者 M 蛋白监测方法（EasyM）。
Clin Cancer Res. 2021 Sep 15;27(18):5028-5037. doi: 10.1158/1078-0432.CCR-21-0649. Epub 2021 Jul 1.
6
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.质谱法评估多发性骨髓瘤和相关疾病中的单克隆蛋白：国际骨髓瘤工作组质谱学委员会报告。
Blood Cancer J. 2021 Feb 1;11(2):24. doi: 10.1038/s41408-021-00408-4.
7
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.一项大型荟萃分析确立了 MRD 阴性在多发性骨髓瘤患者长期生存结局中的作用。
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
8
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的新一代流式检测技术。
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
9
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.循环肿瘤 DNA 分析显示空间突变异质性与骨髓瘤疾病复发一致。
Leukemia. 2017 Aug;31(8):1695-1705. doi: 10.1038/leu.2016.366. Epub 2016 Nov 30.
10
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.